Synthetic biomimetic supra molecular Biovector (SMBV) particles for nasal vaccine delivery.
For the optimal delivery of antigens to mucosal tissues, especially as nasal sprays, protein antigen alone is often not sufficient. A clear need for nasal delivery systems has therefore evolved, especially for Influenza A vaccines. Such technologies will be even more essential for new modern vaccines based on recombinant antigens. Here we describe synthetic biomimetic supra molecular Biovector (SMBV) which have proven in preclinical and clinical evaluation to be suitable candidates for the delivery of nasal vaccines. They also demonstrate the potential to work with multiple antigens and furthermore allow combination with adjuvants. These Biovectors can associate with internal or lipid layer membrane proteins and peptides due to their charged polysaccharide core. The mimicry with viruses is also provided through their size of 60-80 nm, which allows sterilization by filtration. This makes them an ideal tool for the development of modern nasal vaccines, as they have shown to be able to induce the desired types of humoral immunity (serosal and mucosal immunity, IgA and IgG antibodies) as well as cellular immunity (CD4 and CD8 responses).
von Hoegen
P
P
Biovector Therapeutics S.A., Chemin du Chêne Vert, BP 169, 31676 Cedex, Labege, France. PvH@pharmexa.com
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000281:Administration, Intranasal; D000818:Animals; D016207:Cytokines / Q000008:administration & dosage; D016503:Drug Delivery Systems; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage; D014612:Vaccines / Q000008:administration & dosage*; D014614:Vaccines, Synthetic / Q000008:administration & dosage
D000276:Adjuvants, Immunologic; D016207:Cytokines; D007252:Influenza Vaccines; D014612:Vaccines; D014614:Vaccines, Synthetic